http://www.protagonist-inc.com/stock-info 1.0 monthly 2025-10-07 http://www.protagonist-inc.com/publications 1.0 monthly 2025-10-07 http://www.protagonist-inc.com/analyst-coverage 1.0 monthly 2026-01-28 http://www.protagonist-inc.com/events-presentations 1.0 monthly 2026-01-13 http://www.protagonist-inc.com/expanded-access-policy 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/terms-of-use 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/governance 1.0 monthly 2025-10-07 http://www.protagonist-inc.com/join-our-team 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/contact 1.0 monthly 2025-08-21 http://www.protagonist-inc.com/board-of-directors 1.0 monthly 2025-04-27 http://www.protagonist-inc.com/clinical-trials 1.0 monthly 2025-06-05 http://www.protagonist-inc.com/areas-of-focus 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/product-pipeline 1.0 monthly 2026-01-28 http://www.protagonist-inc.com/news 1.0 monthly 2025-05-05 http://www.protagonist-inc.com/leadership 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/technology 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/financials 1.0 monthly 2026-02-26 http://www.protagonist-inc.com/community 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/executive-team 1.0 monthly 2026-03-11 http://www.protagonist-inc.com/careers 1.0 monthly 2024-10-18 http://www.protagonist-inc.com 1.0 monthly 2026-01-13 http://www.protagonist-inc.com/privacy-policy 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/innovation 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/press-releases 1.0 monthly 2025-10-07 http://www.protagonist-inc.com/investor-contacts 1.0 monthly 2025-10-07 http://www.protagonist-inc.com/investor-email-alerts 1.0 monthly 2025-10-07 http://www.protagonist-inc.com/esg 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/culture-values 1.0 monthly 2025-06-05 http://www.protagonist-inc.com/locations 1.0 monthly 2025-11-10 http://www.protagonist-inc.com/blood-cancer-awareness-what-you-need-to-know-now 1.0 monthly 2024-10-18 http://www.protagonist-inc.com/metabolism-scientific-advisory-board 1.0 monthly 2025-07-01 http://www.protagonist-inc.com/scientific-posters-and-presentations 1.0 monthly 2025-10-07 http://www.protagonist-inc.com/barclays-28th-annual-global-healthcare-conference 0.8 monthly 2026-02-25 http://www.protagonist-inc.com/citizens-life-sciences-conference 0.8 monthly 2026-02-25 http://www.protagonist-inc.com/jefferies-biotech-on-the-beach-summit 0.8 monthly 2026-02-24 http://www.protagonist-inc.com/leerink-global-healthcare-conference-miami-fl 0.8 monthly 2026-02-24 http://www.protagonist-inc.com/td-cowen-46th-annual-health-care-conference-boston-ma-march-2-4-2026 0.8 monthly 2026-02-24 http://www.protagonist-inc.com/news/protagonist-ceo-dinesh-v-patel-and-chief-discovery-officer-ashok-bhandari-speak-with-biotechtv 0.8 monthly 2026-02-21 http://www.protagonist-inc.com/jpm26-protagonist-has-a-400m-decision-to-make-its-a-no-brainer 0.8 monthly 2026-01-30 http://www.protagonist-inc.com/protagonist-at-the-j-p-morgan-healthcare-conference 0.8 monthly 2026-01-13 http://www.protagonist-inc.com/events-presentations/protagonist-at-the-evercore-healthcare-conference 0.8 monthly 2025-12-03 http://www.protagonist-inc.com/protagonist-at-the-citi-global-healthcare-conference 0.8 monthly 2025-12-02 http://www.protagonist-inc.com/events-presentatuions/td-cowen-advancements-in-obesity-summit 0.8 monthly 2025-11-26 http://www.protagonist-inc.com/news/protagonist-ceo-dinesh-v-patel-on-our-programs-and-culture-of-partnering-at-jefferies25 0.8 monthly 2025-11-21 http://www.protagonist-inc.com/protagonist-at-the-jefferies-global-healthcare-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/td-cowen-immunology-inflammation-summit 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/ptg-100-an-oral-a4b7-antagonist-peptide-preclinical-development-and-phase-1-and-2a-studies-in-ulcerative-colitis 0.8 monthly 2025-10-07 http://www.protagonist-inc.com/single-and-multiple-dose-pharmacokinetics-and-pharmacodynamics-of-pn-943-a-gastrointestinal-restricted-oral-peptide-antagonist-of-47-in-healthy-volunteers 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/rusfertide-for-the-treatment-of-iron-overload-in-hfe-related-haemochromatosis-an-open-label-multicentre-proof-of-concept-phase-2-trial 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/rusfertide-a-hepcidin-mimetic-for-control-of-erythrocytosis-in-polycythemia-vera 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/contemporary-challenges-in-polycythemia-vera-management-from-the-perspective-of-patients-and-physicians 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/pharmacokinetics-pharmacodynamics-and-tolerability-of-an-aqueous-formulation-of-rusfertide-ptg-300-a-hepcidin-mimetic-in-healthy-volunteers-a-double-blind-first-in-human-study 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/pharmacokinetics-and-pharmacodynamics-of-rusfertide-a-hepcidin-mimetic-following-subcutaneous-administration-of-a-lyophilized-powder-formulation-in-healthy-volunteers 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/multiple-dose-pharmacokinetics-pharmacodynamics-safety-and-tolerability-of-subcutaneous-rusfertide-a-hepcidin-mimetic-in-healthy-subjects 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/an-oral-interleukin-23-receptor-antagonist-peptide-for-plaque-psoriasis 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/jnj-77242113-a-highly-potent-selective-peptide-targeting-the-il-23-receptor-provides-robust-il-23-pathway-inhibition-upon-oral-dosing-in-rats-and-humans 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/frontier-2-a-phase-2b-long-term-extension-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/oral-peptide-therapeutics-as-an-emerging-treatment-modality-in-immune-mediated-inflammatory-diseases-a-narrative-review 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/translational-pharmacokinetics-of-icotrokinra-a-targeted-oral-peptide-that-selectively-blocks-interleukin-23-receptor-and-inhibits-signaling 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/2025-society-for-investigative-dermatology 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/2025-european-academy-of-dermatology-and-venerology-congress 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/63rd-american-society-of-hematology-annual-meeting-and-exposition 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/64th-american-society-of-hematology-annual-meeting-and-exposition 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/65th-american-society-of-hematology-annual-meeting-and-exposition 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/63rd-american-society-of-hematology-ash-annual-meeting-and-exposition 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/american-society-of-clinical-oncology-2022-annual-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/2022-european-hematology-association-eha-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2022-annual-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/64th-american-society-of-hematology-ash-annual-meeting-and-exposition 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/2023-european-hematology-association-eha-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2023-annual-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/15th-international-congress-on-myeloproliferative-neoplasms-mpn-congress 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/65th-american-society-of-hematology-ash-annual-meeting-and-exposition 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/10th-translational-research-conference-myeloproliferative-neoplasms 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/american-society-of-clinical-oncology-2024-annual-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/2024-european-hematology-association-eha-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/2024-american-college-of-clinical-pharmacology-accp-annual-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/16th-international-congress-on-myeloproliferative-neoplasms-mpn-congress 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/66th-american-society-of-hematology-ash-annual-meeting-and-exposition 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/american-society-of-clinical-oncology-2025-annual-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/mpn-workshop-of-the-carolinas-2025 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/society-of-hematologic-oncology-soho-2025-annual-meeting 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/h-c-wainwright-global-investment-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/protagonist-at-the-citigroup-2025-biopharma-conference 0.8 monthly 2025-09-08 http://www.protagonist-inc.com/protagonist-announces-nomination-of-pn-477-an-oral-and-injectable-peptide-development-candidate-for-obesity 0.8 monthly 2025-07-07 http://www.protagonist-inc.com/events/protagonist-therapeutics-to-host-conference-call-to-announce-an-oral-obesity-development-candidate 0.8 monthly 2025-06-27 http://www.protagonist-inc.com/events-presentations/protagonist-at-the-jefferies-global-healthcare-conference 0.8 monthly 2025-06-05 http://www.protagonist-inc.com/news/ceo-dinesh-v-patel-speaks-with-biotechtv-at-asco25 0.8 monthly 2025-06-05 http://www.protagonist-inc.com/events-presentations/post-asco-update-phase-3-verify-study-results 0.8 monthly 2025-07-01 http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference-2025 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/plenary-presentation-on-verify-phase-3-study-with-rusfertide-at-asco-2025 0.8 monthly 2025-05-05 http://www.protagonist-inc.com/news/protagonist-therapeutics-is-one-of-fast-companys-most-innovative-companies-of-2025 0.8 monthly 2025-06-05 http://www.protagonist-inc.com/events-presentations/protagonist-investor-conference-call-and-webcast 0.8 monthly 2025-03-03 http://www.protagonist-inc.com/events-presentations/investor-event-with-kol-insights-on-polycythemia-vera-pv-and-the-hepcidin-mimetic-rusfertide 0.8 monthly 2025-02-06 http://www.protagonist-inc.com/events-presentations/jpm-43rd-annual-healthcare-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/publications/ash-revive-final-analysis-poster 0.8 monthly 2025-09-18 http://www.protagonist-inc.com/news/jj-and-protagonist-announce-phase-3-rial-results-for-icotrokinra 0.8 monthly 2025-06-05 http://www.protagonist-inc.com/events-presenations/protagonist-announces-nomination-of-pn-881-a-potential-best-in-class-oral-peptide-il-17-antagonist-development-candidate 0.8 monthly 2025-05-05 http://www.protagonist-inc.com/news/protagonist-announces-positive-topline-results-from-phase-3-iconic-studies-of-icotrokinra-jnj-2113-a-first-in-class-investigational-targeted-oral-peptide-that-selectively-blocks-the-il-23-receptor 0.8 monthly 2025-06-05 http://www.protagonist-inc.com/events-presentations/the-66th-annual-american-society-of-hematology-ash-annual-meeting 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-26th-annual-global-investment-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/news/jnj-77242113-a-highly-potent-selective-peptide-targeting-the-il-23-receptor-provides-robust-il-23-pathway-inhibition-upon-oral-dosing-in-rats-and-humans 0.8 monthly 2025-06-05 http://www.protagonist-inc.com/events-presentations/eha-2024-oral-presentation-updated-long-term-results-from-the-phase-2-revive-study-investigating-the-hepcidin-mimetic-rusfertide-in-polycythemia-vera-patients 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/the-citizens-jmp-life-sciences-conference-may-13-2024 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference-june-6-2024 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/jefferies-global-healthcare-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/corporate-presentation 0.8 monthly 2026-01-12 http://www.protagonist-inc.com/events-presentations/the-citizens-jmp-life-sciences-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-2nd-annual-autoimmune-inflammatory-disease-virtual-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/6th-annual-guggenheim-healthcare-talks-annual-biotechnology-conference 0.8 monthly 2024-11-25 http://www.protagonist-inc.com/events-presentations/42nd-annual-j-p-morgan-healthcare-conference-jan-8-2023 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/ash-2023-oral-presentation-durability-of-hematocrit-control-in-polycythemia-vera-with-the-first-in-class-hepcidin-mimetic-rusfertide-two-year-follow-up-results-from-the-revive-study 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-2023-oral-presentation-real-world-analysis-of-thromboembolic-event-rates-in-patients-in-the-united-states-with-polycythemia-vera 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-rusfertide-improves-markers-of-iron-deficiency-in-patients-with-polycythemia-vera 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-prevalence-of-second-cancers-in-patients-with-polycythemia-vera-pv-a-retrospective-analysis-of-us-real-world-claims-data 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-2023-poster-presentation-iron-restricted-erythropoiesis-under-hepcidin-mimetic-treatment-pn23114-improves-disease-parameters-in-a-mouse-model-for-sickle-cell-disease 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/protagonist-therapeutics-ceo-on-its-hepcidin-memetic-at-ash23-and-oral-il23-program-in-i-i 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/j-j-notebook-highlights-from-a-day-of-pipeline-and-strategy-discussion 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference082b4611 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/publications/summary-of-malignancies-observed-across-5-phase-2-open-label-clinical-trials-of-the-hepcidin-mimetic-rusfertide 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/publications/oral-il-23-receptor-peptide-antagonist-jnj-2113-the-journey-from-de-novo-discovery-to-phase-3-clinical-development-program 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/jnj-77242113-treatment-induces-a-strong-systemic-pharmacodynamic-response-versus-placebo-in-serum-samples-of-patients-with-plaque-psoriasis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/a-phase-2-randomized-placebo-controlled-dose-ranging-study-of-oral-jnj-77242113-for-the-treatment-of-moderate-to-severe-plaque-psoriasis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/improving-access-to-medicines-ensuring-diverse-representation 0.8 monthly 2024-11-25 http://www.protagonist-inc.com/news/protagonist-inclusion-by-the-numbers 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/blood-cancer-awareness-what-you-need-to-know-now 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/join-our-polycythemia-vera-verify-clinical-study 0.8 monthly 2025-05-05 http://www.protagonist-inc.com/news/cancer-moonshot-how-were-helping-patients 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/polycythemia-vera-mechanism-of-disease 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/ceo-dinesh-patel-talks-culture-collaboration-and-courage 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/formulas-for-success-from-biotechs-that-leaped-in-value-despite-the-downturn 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/news/amgen-tipped-to-keep-otezla-market-share-in-fight-with-bms-sotyktu-leaving-opportunity-for-j-j 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/targeted-therapy-of-uncontrolled-erythrocytosis-in-polycythemia-vera-with-the-hepcidin-mimetic-rusfertide-blinded-randomizated-withdrawal-results-of-the-phase-2-revive-study 0.8 monthly 2025-10-06 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-25th-annual-global-investment-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/wells-fargo-2023-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/rusfertide-in-pv-revive-late-breaking-oral-presentation-june-11-2023 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/pharmacokinetic-and-pharmacodynamic-effects-of-rusfertide-in-polycythemia-vera-results-from-an-ongoing-phase-2-study-in-patients-with-elevated-hematocrit-values 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/rusfertide-ptg-300-improves-polycythemia-vera-pv-related-symptoms-in-pv-patients 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-healthcare-conference-2023 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/2023-world-congress-of-dermatology 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/first-in-class-oral-peptide-systemically-targeting-the-il-23-pathway 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/2023-annual-congress-of-the-european-hematology-association 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/realworld-treatments-and-thrombotic-events-in-polycythemia-vera-patients-in-the-usa 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/j-p-morgan-2023-healthcare-conference-company-presentation 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/ash-2022-poster-presentation-rusfertide-analog-pn23114-as-a-hepcidin-mimetic-provides-efficacy-benefits-in-conjunction-with-phlebotomy-in-mouse-model-for-hereditary-hemochromatosis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/32nd-annual-piper-sandler-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/raymond-james-human-health-innovations-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ueg-week 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/41st-annual-j-p-morgan-health-care-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/cyclic-tetrapeptides-via-the-ring-contraction-strategy-chemical-techniques-useful-for-their-identification 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/library-of-biphenyl-privileged-substructures-using-a-safety-catch-linker-approach 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/defining-scaffold-geometries-for-interacting-with-proteins-geometrical-classification-of-secondary-structure-linking-regions 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/conformational-searching-using-a-population-based-incremental-learning-algorithm 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/discovery-and-characterization-of-a-potent-interleukin-6-binding-peptide-with-neutralizing-activity-in-vivo 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/clustering-of-disulfide-rich-peptides-provides-scaffolds-for-hit-discovery-by-phage-display-application-to-interleukin-23 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/orally-delivered-peptides-for-treatment-of-inflammatory-bowel-disease 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/oral-peptides-with-dual-mu-delta-opioid-receptor-agonist-activities-are-superior-to-eluxadoline-in-preclinical-models-of-ibs-d 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/discovery-and-characterization-of-novel-oral-peptide-antagonists-of-human-il-23-receptor-that-are-efficacious-in-a-rat-model-of-ibd 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/discovery-of-novel-oral-peptide-antagonists-of-il-23-receptor-that-are-efficacious-in-rat-model-of-ibd 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/the-biomarker-profile-of-ptg-200-an-oral-peptide-antagonist-of-il-23-receptor-tracks-with-efficacy-in-preclinical-model-of-ibd 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/uegw-2019-safety-tolerability-and-pharmacokinetics-of-ptg-200-an-oral-gi-restricted-peptide-antagonist-of-il-23-receptor-in-normal-healthy-volunteers 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/acg-2019-safety-tolerability-and-pharmacokinetics-of-ptg-200-an-oral-gi-restricted-peptide-antagonist-of-il-23-receptor-in-normal-healthy-volunteers 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/integrin-47-discovery-of-gut-restrictive-oral-peptide-antagonists-that-are-active-in-murine-models-of-inflammatory-bowel-disease 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/preclinical-characterization-of-ptg-100-an-oral-47-integrin-peptide-antagonist-for-treatment-of-ulcerative-colitis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/ptg-100-an-oral-peptide-antagonist-of-integrin-47-that-alters-trafficking-of-gut-homing-t-cells-in-preclinical-animal-models 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/establishing-the-human-equivalent-dose-for-ptg-100-an-oral-peptide-antagonist-of-integrin-47 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/safety-pharmacokinetics-and-pharmacodynamics-of-the-novel-oral-peptide-therapeutic-ptg-100-47-integrin-antagonist-in-normal-healthy-volunteers 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/pharmacokinetics-and-pharmacodynamics-following-oral-administration-of-ptg-100-a-peptide-antagonist-of-integrin-47 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/model-based-predictions-of-the-ptg-100-pharmacodynamic-responses-in-ulcerative-colitis-patients 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/ptg-100-an-oral-gut-restricted-peptide-47-antagonist-induces-clinical-and-histologic-remission-in-patients-with-moderate-to-severely-active-ulcerative-colitis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/the-oral-47-integrin-specific-antagonist-pn-10943-is-more-effective-than-ptg-100-in-multiple-preclinical-studies 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/pn-943-an-oral-47-integrin-antagonist-inhibits-madcam1-mediated-proliferation-and-cytokine-release-from-cd4--t-cells-independent-of-trafficking 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/single-and-multiple-dose-pharmacokinetics-and-pharmacodynamics-of-pn-943-a-gastrointestinal-restricted-oral-peptide-antagonist-of-47-in-healthy-volunteers 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/a-phase-2-randomized-double-blind-placebocontrolled-multi-center-study-to-evaluate-the-safety-and-efficacy-of-the-oral-gut-restricted-47-integrin-peptide-antagonist-pn-943 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-iron-overload 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-iron-overload-diseases 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-chronic-anemia-in-hemoglobinopathy-diseases 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/hepcidin-mimetic-ptg-300-induces-dose-related-and-sustained-reductions-in-serum-iron-and-transferrin-saturation-in-healthy-subjects 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/regulation-of-iron-homeostasis-by-ptg-300-improves-disease-parameters-in-mouse-models-for-beta-thalassemia-and-hereditary-hemochromatosis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/mechanism-of-systemic-iron-regulation-and-hematocrit-control-by-hepcidin-peptidomimetics-in-pre-clinical-models-nov-2020 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/ptg-300-eliminates-the-need-for-therapeutic-phlebotomy-in-both-low-and-high-risk-polycythemia-vera-patients-dec-2020 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/hepcidin-peptidomimetics-oral-efficacy-in-pre-clinical-disease-models-of-iron-overload-and-erythrocytosis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/ptg-300-eliminates-the-need-for-therapeutic-phlebotomy-in-both-low-and-high-risk-polycythemia-vera-patients 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/regulation-of-iron-homeostasis-by-ptg-300-improves-disease-parameters-in-mouse-models-for-beta-thalassemia-hereditary-hemochromatosis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/mechanism-of-systemic-iron-regulation-and-hematocrit-control-by-hepcidin-peptidomimetics-in-pre-clinical-models 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/hepcidin-peptidomimetics-oral-efficacy-in-pre-clinical-disease-models-for-iron-overload-and-erythrocytosis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/the-hepcidin-mimetic-rusfertide-as-a-treatment-for-hereditary-hemochromatosis 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/ptg-300-rusfertide-treatment-interruption-reverses-hematological-gains-and-restores-therapeutic-benefit-on-reinitiation-in-subjects-with-polycythemia-vera 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/rusfertide-for-polycythemia-vera-similar-dosing-in-patients-receiving-therapeutic-phlebotomy-alone-or-in-combination-with-cytoreductive-treatment 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/publications/subgroup-analysis-of-adverse-events-following-rusfertide-dosing-in-revive-a-phase-2-study-in-patients-with-polycythemia-vera 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-prescriptions-for-success-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/2016-advances-in-inflammatory-bowel-diseases-crohns-colitis-foundation-of-americas-clinical-research-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/bioeurope-2016 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-252nd-american-chemical-society-national-meeting-exposition 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-2017-prescriptions-for-success-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-stifel-2017-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/2017-cantor-fitzgerald-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-business-update 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-25-2017 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/digestive-diseases-week 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/oxford-globals-4th-annual-peptide-congress 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/drug-discovery-chemistry 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/oppenheimer-co-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/barclays-global-healthcare-conference-2017 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/leerink-partners-6th-annual-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/12th-congress-of-ecco-european-crohn-s-and-colitis-organization 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/bmo-capital-markets-2018-prescriptions-for-success-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call-2018 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/united-european-gastroenterology-week-meeting 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/cantor-fitzgerald-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/propel-study-and-ptg-100-program-update-conference-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/2018-jmp-securities-life-sciences-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/hepcidin-mimetic-ptg-300-for-treatment-of-ineffective-erythropoiesis-and-chronic-anemia-in-hemoglobinopathy-diseases 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/hepcidin-mimetic-ptg-300-induces-dose-related-and-sustained-reductions-in-serum-iron-and-transferrin-saturation-in-healthy-subjects 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/23rd-congress-of-the-european-hematology-association-eha 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/digestive-diseases-week-ddw-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-29-2018 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-conference-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-28th-annual-oppenheimer-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-at-barclay-s-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-inc-2017-year-end-update-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/btigs-2018-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/leerink-partners-7th-annual-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/piper-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ptg-300-beta-thalassemia-update 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/stifel-2019-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/cantor-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-co-2019-annual-healthcare-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/bmo-2019-prescription-for-success-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-jun-7-2019 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/digestive-disease-week-ddw 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call-may-8-2019 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-co-global-life-sciences-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/q4-2018-protagonist-therapeutics-inc-earnings-conference-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/leerink-partners-8th-annual-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/research-and-development-r-d-and-corporate-update 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/62nd-ash-annual-meeting-and-exposition 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference-2020 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-22nd-annual-global-investment-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/jefferies-next-generation-ibd-therapeutics-virtual-summit 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-ptg-300-opportunity-update-webinar 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/bmo-prescriptions-for-success-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-virtual-healthcare-conference-jun-3-2020 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-may-28-2020 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-corporate-and-r-d-update-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-2019-year-end-update-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/svb-leerink-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-2021-presentation 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presenations/jmp-securities-hematology-and-oncology-summit-1-40-pm-et 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/piper-sandler-33rd-annual-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-london-healthcare-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/the-liver-meeting-aasld-2021-oral-presentation 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-next-generation-ibd-therapeutics-summit 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/protagonist-regulatory-update-conference-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/investor-call-on-updated-janssen-agreement 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/european-hematology-association-eha-2021-annual-congress 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/eha2021-corporate-event-conference-call-and-webcast 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-virtual-healthcare-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders-2021 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-corporate-update-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/protagonist-therapeutics-fourth-quarter-and-year-end-financial-results 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-global-life-sciences-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/10th-annual-svb-leerink-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/39th-annual-j-p-morgan-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/h-c-wainwright-bioconnect-2022-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/40th-annual-j-p-morgan-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/11th-annual-svb-leerink-global-healthcare-conference 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/pn-943-phase-2-data-readout-conference-call 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ideal-pn-943-ddw-2022-presentation 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/annual-meeting-of-stockholders 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/asco-2022-presentation 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/jefferies-healthcare-conference 0.8 monthly 2025-11-19 http://www.protagonist-inc.com/events-presentations/eha-2022-poster-presentation 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/california-life-sciences-cancer-moonshot 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/soho-rusfertide-presentation 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-2022-poster-presentation-dec-10-2022 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-annual-meeting-exposition 0.8 monthly 2024-10-18 http://www.protagonist-inc.com/events-presentations/ash-2022-poster-presentation 0.8 monthly 2024-10-18